

ORIOR TECHNOLOGIES INC.
COMPLETION OF QUALIFYING TRANSACTION AND RECOMMENCEMENT
OF TRADING ON MAY 5TH

TORONTO, May 1, Orior Technologies Inc. ("**Orior**"), a Capital Pool Company, announces today that it has closed its qualifying transaction (the "**Transaction**") with AIM Health Group Ltd. and expects its shares to recommence trading on the TSX Venture Exchange (the "**Exchange**") on May 5, 2008 under the symbol "**AHG**".

In connection with the closing of the Transaction, Orior issued an aggregate of 51,653,741 common shares in exchange for all of the common shares of AIM outstanding on the closing date, including:

- (i) 13,970,878 Orior common shares issued to two companies related to B.E.S.T. Funds (such companies and other companies related to B.E.S.T. Funds collectively known as "**BEST Funds**"), which had acquired AIM common shares for an aggregate subscription price of approximately \$3 million pursuant to a subscription agreement dated February 5, 2008,
- (ii) 666,666 Orior common shares issued by BEST Funds, which had acquired AIM common shares upon the exercise of nominal value warrants granted to BEST Funds as part of a \$2 million debenture financing completed between AIM and BEST Funds in 2007 (with such Orior common shares being escrowed pursuant to Exchange requirements), and
- (iii) 3,682,864 Orior common shares issued in exchange for AIM common shares issuable upon automatic conversion of outstanding AIM convertible notes in the aggregate principal amount of approximately \$0.7 million.

In addition, Orior issued an aggregate of 1,323,018 common shares in exchange for the outstanding shares of several AIM subsidiary companies not already owned by AIM.

Following closing of the Transaction and related transactions, Orior has 60,326,759 common shares issued and outstanding (of which 29,405,314 common shares are held in escrow pursuant to Exchange requirements which provide for releases in stages over a 72 month period (as to 5% every 6 months for the first 2 years and 10% every 6 months thereafter)) and 3,540,000 common shares reserved for issuance.

The new board of directors of Orior will consist of KC Lim (as Chair), Lu Barbuto, Gilbert Sharpe and John McLaughlin. Mr. Lim is the Managing Director of Pluris Advisory Inc., a company that he co-founded in November 2004. Prior to that, Mr. Lim assisted in setting up Bank of Montreal Capital Corporation and was its Chief Operating Officer and Managing Director from October 1995 to April 2004. Dr. Barbuto is the founder and the President and Chief Executive Officer of AIM. Mr. Sharpe is a partner in the law firm of Fasken Martineau DuMoulin LLP and acts as a Health Law consultant to the Ontario Ministry of Health. He graduated with a Masters in Law from Osgoode Hall Law School, York University in 1973 and holds numerous academic positions. Mr. McLaughlin is the President of Tall Oak Management Inc., a privately held management and investment company. From 1984 to 2002, he was with Extendicare Inc., acting as President and COO of Extendicare Health Services Inc. and Managing Director of Extendicare (UK) Ltd. He is currently the Chair of Futuremed Healthcare Income Fund. The Orior management team will be led by Lu Barbuto as President and Chief Executive Officer and Greg Van Staveren as Chief Financial Officer.

It is expected that the common shares of Orior will commence trading on Tier 2 of the Exchange on May 5, 2008 under the symbol "**AHG**".

Additional information concerning Orior and the Transaction, including the Filing Statement dated March 28, 2008 filed by Orior in connection with the Transaction, is available on www.sedar.com.

Caution Concerning Forward-Looking Statements

Certain statements made in this press release, including, but not limited to, the proposed qualifying transaction and the timing of the closing of the proposed qualifying transaction, and other statements that are not historical facts, are forward-looking statements and are subject to important risks, uncertainties and assumptions. In particular, in making these statements, Orior has assumed, among other things, that the proposed qualifying transaction will receive the required regulatory approval and that the other conditions to the transaction can be satisfied in accordance with their terms. The results or events predicted in these forward-looking statements may differ materially from actual results or events. As a result, readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release represent our expectations as of the date hereof. We disclaim any intention and assume no obligation to update or revise any forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS IN NO WAY PASSED UPON THE MERITS OF THE PROPOSED TRANSACTION AND HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE.

- 30 -

For further information:

AIM Health Group Ltd.
Lu Barbuto, President or
Greg Van Staveren, CFO
905-475-3353

Orior Technologies Inc.
KC Lim, Chairman
416-360-4360